News for 'boehringer-ingelheim'

Diabetes Drug Price Drops 90%

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.

Wockhardt launches prostate drug in US market

Pharma major Wockhardt on Wednesday said it has launched Tamsulosin capsules, indicated for problem of prostate enlargement, in the US market on the day one of the expiry of patent covering the drug.

Cipla signs global supply deal with Boehringer

Glenmark, Zydus get US go-ahead for Meloxicam

IIM-C records 100% placement, avg salary up by 4%

172 firms participated in the final placement process.

Price relief for diabetes patients as drugs go off patent

At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of drugs - SGLT-2 inhibitors or gliflozins.

Earning woes drag markets lower; TCS, HUL lead fall

Earning woes drag markets lower; TCS, HUL lead fall.

Prices of key diabetes, cancer drugs may drop by 25%

A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.

US FDA tightens regulatory noose on Indian drug firms

Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter